Schering AG Licenses Sonus Tocosol Paclitaxel; NDA Slated For Year-End 2007
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering AG and Sonus plan to submit a 505(b)(2) NDA by the end of 2007 for use of Sonus' Tocosol paclitaxel formulation in metastatic breast cancer